Central Nervous System Infection with Histoplasma capsulatum
Abstract
:1. Introduction
2. Clinical Presentation
2.1. Risk Factors
2.2. Symptoms
2.3. Physical Exam Findings
2.4. Diagnosis
3. Treatment and Subsequent Diagnostic Testing
4. Summary
Funding
Conflicts of Interest
References
- Darling, S.T. A protozoon general infectoin producing pseudotubercles in the lungs and focal necrosis in the liver, spleen, and lymph nodes. JAMA 1906, XLVI, 1283–1285. [Google Scholar] [CrossRef]
- Bahr, N.C.; Antinori, S.; Wheat, L.J.; Sarosi, G.A. Histoplasmosis infections worldwide: Thinking outside of the Ohio river valley. Curr. Trop. Med. Rep. 2015, 2, 70–80. [Google Scholar] [CrossRef] [PubMed]
- Dodd, K.; Tompkins, E. A case of histoplasmosis of darling in an infant. Am. J. Trop. Med. 1934, 14, 127–137. [Google Scholar] [CrossRef]
- Shapiro, J.L.; Lux, J.J.; Sprofkin, B.E. Histoplasmosis of the central nervous system. Am. J. Pathol. 1955, 31, 319–335. [Google Scholar] [PubMed]
- Wheat, L.J.; Batteiger, B.E.; Sathapatayavongs, B. Histoplasma capsulatum infections of the central nervous system. A clinical review. Medicine 1990, 69, 244–260. [Google Scholar] [CrossRef] [PubMed]
- Wheat, J.; French, M.; Batteiger, B.; Kohler, R. Cerebrospinal fluid histoplasma antibodies in central nervous system histoplasmosis. Arch. Intern. Med. 1985, 145, 1237–1240. [Google Scholar] [CrossRef] [PubMed]
- Marukutira, T.; Huprikar, S.; Azie, N.; Quan, S.P.; Meier-Kriesche, H.U.; Horn, D.L. Clinical characteristics and outcomes in 303 hiv-infected patients with invasive fungal infections: Data from the prospective antifungal therapy alliance registry, a multicenter, observational study. HIV Aids 2014, 6, 39–47. [Google Scholar] [CrossRef] [PubMed]
- Cuellar-Rodriguez, J.; Avery, R.K.; Lard, M.; Budev, M.; Gordon, S.M.; Shrestha, N.K.; van Duin, D.; Oethinger, M.; Mawhorter, S.D. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin. Infect. Dis. 2009, 49, 710–716. [Google Scholar] [CrossRef]
- Vergidis, P.; Avery, R.K.; Wheat, L.J.; Dotson, J.L.; Assi, M.A.; Antoun, S.A.; Hamoud, K.A.; Burdette, S.D.; Freifeld, A.G.; McKinsey, D.S.; et al. Histoplasmosis complicating tumor necrosis factor-alpha blocker therapy: A retrospective analysis of 98 cases. Clin. Infect. Dis. 2015, 61, 409–417. [Google Scholar] [CrossRef]
- Smith, J.A.; Kauffman, C.A. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs 2009, 69, 1403–1415. [Google Scholar] [CrossRef]
- Wheat, J.; Myint, T.; Guo, Y.; Kemmer, P.; Hage, C.; Terry, C.; Azar, M.M.; Riddell, J.; Ender, P.; Chen, S.; et al. Central nervous system histoplasmosis: Multicenter retrospective study on clinical features, diagnostic approach and outcome of treatment. Medicine 2018, 97, e0245. [Google Scholar] [CrossRef] [PubMed]
- Schestatsky, P.; Chedid, M.F.; Amaral, O.B.; Unis, G.; Oliveira, F.M.; Severo, L.C. Isolated central nervous system histoplasmosis in immunocompetent hosts: A series of 11 cases. Scand. J. Infect. Dis. 2006, 38, 43–48. [Google Scholar] [CrossRef] [PubMed]
- Estrada-Bellmann, I.; Camara-Lemarroy, C.R.; Flores-Cantu, H.; Calderon-Hernandez, H.J.; Villareal-Velazquez, H.J. Hemichorea in a patient with hiv-associated central nervous system histoplasmosis. Int. J. Std Aids 2016, 27, 75–77. [Google Scholar] [CrossRef] [PubMed]
- Batra, V.; Khararjian, A.; Wheat, J.; Zhang, S.X.; Crain, B.; Baras, A. From suspected creutzfeldt-jakob disease to confirmed histoplasma meningitis. BMJ Case Rep. 2016, 2016. [Google Scholar] [CrossRef] [PubMed]
- Bloch, K.C.; Myint, T.; Raymond-Guillen, L.; Hage, C.A.; Davis, T.E.; Wright, P.W.; Chow, F.C.; Woc-Colburn, L.; Khairy, R.N.; Street, A.C.; et al. Improvement in diagnosis of histoplasma meningitis by combined testing for histoplasma antigen and immunoglobulin g and immunoglobulin m anti-histoplasma antibody in cerebrospinal fluid. Clin. Infect. Dis. 2018, 66, 89–94. [Google Scholar] [CrossRef] [PubMed]
- Wheat, L.J.; Slama, T.G.; Norton, J.A.; Kohler, R.B.; Eitzen, H.E.; French, M.L.; Sathapatayavongs, B. Risk factors for disseminated or fatal histoplasmosis. Analysis of a large urban outbreak. Ann. Intern. Med. 1982, 96, 159–163. [Google Scholar] [CrossRef] [PubMed]
- Bono, J.L.; Legendre, A.M.; Scalarone, G.M. Detection of antibodies and delayed hypersensitivity with rotofor preparative ief fractions of blastomyces dermatitidis yeast phase lysate antigen. J. Med. Vet. Mycol. 1995, 33, 209–214. [Google Scholar] [CrossRef]
- Connolly, P.A.; Durkin, M.M.; Lemonte, A.M.; Hackett, E.J.; Wheat, L.J. Detection of histoplasma antigen by a quantitative enzyme immunoassay. Clin. Vaccine Immunol. 2007, 14, 1587–1591. [Google Scholar] [CrossRef] [PubMed]
- Theel, E.S.; Jespersen, D.J.; Harring, J.; Mandrekar, J.; Binnicker, M.J. Evaluation of an enzyme immunoassay for detection of histoplasma capsulatum antigen from urine specimens. J. Clin. Microbiol. 2013, 51, 3555–3559. [Google Scholar] [CrossRef]
- Falci, D.R.; Monteiro, A.A.; Braz Caurio, C.F.; Magalhaes, T.C.O.; Xavier, M.O.; Basso, R.P.; Melo, M.; Schwarzbold, A.V.; Ferreira, P.R.A.; Vidal, J.E.; et al. Histoplasmosis, an underdiagnosed disease affecting people living with hiv/aids in brazil: Results of a multicenter prospective cohort study using both classical mycology tests and histoplasma urine antigen detection. Open Forum Infect. Dis. 2019, 6, ofz073. [Google Scholar] [CrossRef]
- Myint, T.; Chow, F.C.; Bloch, K.C.; Raymond-Guillen, L.; Davis, T.E.; Wright, P.W.; Woc-Colburn, L.; Khairy, R.N.; Street, A.C.; Yamamoto, T.; et al. Detection of (1,3)-beta-d-glucan in cerebrospinal fluid in histoplasma meningitis. J. Clin. Microbiol. 2018, 56. [Google Scholar] [CrossRef] [PubMed]
- Babady, N.E.; Buckwalter, S.P.; Hall, L.; Le Febre, K.M.; Binnicker, M.J.; Wengenack, N.L. Detection of blastomyces dermatitidis and histoplasma capsulatum from culture isolates and clinical specimens by use of real-time pcr. J. Clin. Microbiol. 2011, 49, 3204–3208. [Google Scholar] [CrossRef] [PubMed]
- Wheat, L.J.; Freifeld, A.G.; Kleiman, M.B.; Baddley, J.W.; McKinsey, D.S.; Loyd, J.E.; Kauffman, C.A.; Infectious Diseases Society of, A. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of america. Clin. Infect. Dis. 2007, 45, 807–825. [Google Scholar] [CrossRef] [PubMed]
- Botero Aguirre, J.P.; Restrepo Hamid, A.M. Amphotericin b deoxycholate versus liposomal amphotericin b: Effects on kidney function. Cochrane Database Syst. Rev. 2015, CD010481. [Google Scholar] [CrossRef] [PubMed]
- Johnson, P.C.; Wheat, L.J.; Cloud, G.A.; Goldman, M.; Lancaster, D.; Bamberger, D.M.; Powderly, W.G.; Hafner, R.; Kauffman, C.A.; Dismukes, W.E.; et al. Safety and efficacy of liposomal amphotericin b compared with conventional amphotericin b for induction therapy of histoplasmosis in patients with aids. Ann. Intern. Med. 2002, 137, 105–109. [Google Scholar] [CrossRef] [PubMed]
- Groll, A.H.; Giri, N.; Petraitis, V.; Petraitiene, R.; Candelario, M.; Bacher, J.S.; Piscitelli, S.C.; Walsh, T.J. Comparative efficacy and distribution of lipid formulations of amphotericin b in experimental candida albicans infection of the central nervous system. J. Infect. Dis. 2000, 182, 274–282. [Google Scholar] [CrossRef]
- Andes, D.; Pascual, A.; Marchetti, O. Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrob. Agents Chemother. 2009, 53, 24–34. [Google Scholar] [CrossRef]
- Lestner, J.M.; Roberts, S.A.; Moore, C.B.; Howard, S.J.; Denning, D.W.; Hope, W.W. Toxicodynamics of itraconazole: Implications for therapeutic drug monitoring. Clin. Infect. Dis. 2009, 49, 928–930. [Google Scholar] [CrossRef]
- Renschler, J.; Albers, A.; Sinclair-Mackling, H.; Wheat, L.J. Comparison of compounded, generic, and innovator-formulated itraconazole in dogs and cats. J. Am. Anim. Hosp. Assoc. 2018, 54, 195–200. [Google Scholar] [CrossRef]
- Pasqualotto, A.C.; Denning, D.W. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int. J. Antimicrob. Agents 2007, 30, 93–94. [Google Scholar] [CrossRef]
- Abuhelwa, A.Y.; Foster, D.J.; Mudge, S.; Hayes, D.; Upton, R.N. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral suba-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob. Agents Chemother. 2015, 59, 5681–5696. [Google Scholar] [CrossRef] [PubMed]
- Pharma, M. Suba-Itraconazole Package Insert; US Food Drug Administration: Silver Spring, MD, USA, 2018.
- Knapp, S.; Turnherr, M.; Dekan, G.; Willinger, B.; Stingl, G.; Rieger, A. A case of hiv-associated cerebral histoplasmosis successfully treated with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 1999, 18, 658–661. [Google Scholar] [CrossRef] [PubMed]
- Bamberger, D.M. Successful treatment of multiple cerebral histoplasmomas with itraconazole. Clin. Infect. Dis. 1999, 28, 915–916. [Google Scholar] [CrossRef] [PubMed]
- Saccente, M.; McDonnell, R.W.; Baddour, L.M.; Mathis, M.J.; Bradsher, R.W. Cerebral histoplasmosis in the azole era: Report of four cases and review. South. Med. J. 2003, 96, 410–416. [Google Scholar] [CrossRef] [PubMed]
- Haynes, R.R.; Connolly, P.A.; Durkin, M.M.; LeMonte, A.M.; Smedema, M.L.; Brizendine, E.; Wheat, L.J. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J. Infect. Dis. 2002, 185, 1830–1832. [Google Scholar] [CrossRef] [PubMed]
- Wheat, L.J.; Connolly, P.; Smedema, M.; Durkin, M.; Brizendine, E.; Mann, P.; Patel, R.; McNicholas, P.M.; Goldman, M. Activity of newer triazoles against histoplasma capsulatum from patients with aids who failed fluconazole. J. Antimicrob. Chemother. 2006, 57, 1235–1239. [Google Scholar] [CrossRef] [PubMed]
- Wheat, L.J.; Connolly, P.; Smedema, M.; Brizendine, E.; Hafner, R.; AIDS Clinical Trials Group and the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin. Infect. Dis. 2001, 33, 1910–1913. [Google Scholar] [CrossRef] [PubMed]
- Spec, A.; Connolly, P.; Montejano, R.; Wheat, L.J. In vitro activity of isavuconazole against fluconazole-resistant isolates of histoplasma capsulatum. Med. Mycol. 2018, 56, 834–837. [Google Scholar] [CrossRef] [PubMed]
- Schmitt-Hoffmann, A.H.; Kato, K.; Townsend, R.; Potchoiba, M.J.; Hope, W.W.; Andes, D.; Spickermann, J.; Schneidkraut, M.J. Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats. Antimicrob. Agents Chemother. 2017, 61. [Google Scholar] [CrossRef]
- Lamoth, F.; Mercier, T.; Andre, P.; Pagani, J.L.; Pantet, O.; Maduri, R.; Guery, B.; Decosterd, L.A. Isavuconazole brain penetration in cerebral aspergillosis. J. Antimicrob. Chemother. 2019, 74, 1751–1753. [Google Scholar] [CrossRef]
- Calcagno, A.; Baietto, L.; De Rosa, F.G.; Tettoni, M.C.; Libanore, V.; Bertucci, R.; D’Avolio, A.; Di Perri, G. Posaconazole cerebrospinal concentrations in an hiv-infected patient with brain mucormycosis. J. Antimicrob. Chemother. 2011, 66, 224–225. [Google Scholar] [CrossRef] [PubMed]
- Reinwald, M.; Uharek, L.; Lampe, D.; Grobosch, T.; Thiel, E.; Schwartz, S. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. Bone Marrow Transpl. 2009, 44, 269–270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Restrepo, A.; Tobon, A.; Clark, B.; Graham, D.R.; Corcoran, G.; Bradsher, R.W.; Goldman, M.; Pankey, G.; Moore, T.; Negroni, R.; et al. Salvage treatment of histoplasmosis with posaconazole. J. Infect. 2007, 54, 319–327. [Google Scholar] [CrossRef] [PubMed]
- Thompson, G.R., 3rd; Rendon, A.; Ribeiro Dos Santos, R.; Queiroz-Telles, F.; Ostrosky-Zeichner, L.; Azie, N.; Maher, R.; Lee, M.; Kovanda, L.; Engelhardt, M.; et al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin. Infect. Dis. 2016, 63, 356–362. [Google Scholar] [CrossRef] [PubMed]
Clinical Characteristic | Percent of Cases |
---|---|
Immune compromised | 71% |
Typical symptoms of meningitis | 86% |
Symptoms for more than 2 weeks | 65% |
Lymphocytic CSF pleocytosis | 50% |
Mass lesion on CNS imaging | 20% |
Test | Sensitivity | Specificity |
---|---|---|
ID or CF antibody [17] | 22/43 (51%) | 22/23 (96%) |
Cytopathology-CSF [11] | 2/11 (18%) | Not done |
Histopathology-Brain [11] | 6/11 (55%) | Not done |
Culture-CSF [17] | 9/47 (19%) | 119/119 (100%) |
Culture-Brain [11] | 2/4 (50%) | Not done |
Histoplasma antigen EIA * [17] | 36/50 (78%) | 140/154 (97%) |
IgG or IgM anti-Histoplasma antibody EIA * [17] | 37/45 (82%) | 142/153 (93%) |
antigen or anti-Histoplasma antibody EIA * [17] | 48/49 (98%) | 139/153 (91%) |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Riddell, J., IV; Wheat, L.J. Central Nervous System Infection with Histoplasma capsulatum. J. Fungi 2019, 5, 70. https://doi.org/10.3390/jof5030070
Riddell J IV, Wheat LJ. Central Nervous System Infection with Histoplasma capsulatum. Journal of Fungi. 2019; 5(3):70. https://doi.org/10.3390/jof5030070
Chicago/Turabian StyleRiddell, James, IV, and L. Joseph Wheat. 2019. "Central Nervous System Infection with Histoplasma capsulatum" Journal of Fungi 5, no. 3: 70. https://doi.org/10.3390/jof5030070